Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 372-376

  Locatelli, Franco ^a,b   Pagliara, Daria ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cord blood transplantation; Mixed chimerism; Sickle cell disease

Indexed keywords

THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CEREBROVASCULAR DISEASE; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ENGRAFTMENT; EVENT FREE SURVIVAL; FOLLOW UP; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RECURRENT DISEASE; REDUCED TOXICITY CONDITIONING; REVIEW; SICKLE CELL ANEMIA; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION;

ANEMIA, SICKLE CELL; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862268473     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24177     Document Type: Review

References (52)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762- 769.
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376: 2018- 2031.
3. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: A clinic-based population study. Lancet 2001; 357: 680- 683.
4. Walters MC, Nienhuis AW, Vichinsky E. Novel therapeutic approaches in sickle cell disease. Am Soc Haematol Edu Prog Book 2002; 319- 338.
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639- 1644.
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332: 1317- 1322.
7. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960- 1964.
8. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645- 1651.
9. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358: 1362- 1369.
10. Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984; 311: 780- 783.
11. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369- 376.
12. Walters M, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918- 1924.
13. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1- 6.
14. Bernaudin F, Socié G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749- 2756.
15. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137: 479- 485.
16. Brachet C, Azzi N, Demulder A, et al. Hydroxyurea treatment for sickle cell disease: Impact on haematopoietic stem cell transplantation's outcome. Bone Marrow Transplant 2004; 33: 799- 803.
17. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: The time is now. Blood 2011; 118: 1197- 1207.
18. Locatelli F, De Stefano P. New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br J Haematol 2004; 125: 3- 11.
19. Adams RJ, Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769- 2778.
20. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011; 117: 1130- 1140.
21. Hoppe CC, Walters MC. Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol 2001; 13: 85- 90.
22. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560- 565.
23. Ferrara JL, Levine JE, Reddy P, et al. Graft versus host disease. Lancet 2009; 373: 1550- 1561.
24. Walters MC, Patience M, Leisenring W, et al. Stable mixed haematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665- 673.
25. Wu CJ, Gladwin M, Tisdale J, et al. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol 2007; 139: 504- 507.
26. Kean LS, Manci EA, Perry J, et al. Chimerism and cure: Hematologic and pathologic correction of murine sickle cell disease. Blood 2003; 102: 4582- 4593.
27. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for treatment of thalassemia. Blood 1996; 87: 3494- 3499.
28. Lisini D, Zecca M, Giorgiani G, et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given allogeneic cord blood transplantation from an HLA-identical sibling. Haematologica 2008; 93: 1859- 1867.
29. Hill RS, Petersen FB, Storb R, et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811- 816.
30. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690- 1697.
31. Sykes M, Eisenthal A, Sachs DH. Mechanism of protection from graft-versus-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 1988; 140: 2903- 2911.
32. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999; 68: 459- 467.
33. Gluckman E, Locatelli F. Umbilical cord blood transplants. Curr Opin Haematol 2000; 7: 353- 357.
34. Kurtzberg J, Update on umbilical cord blood transplantation. Curr Opin Paedtr 2009; 21: 22- 29.
35. Rocha V, Wagner JE, Sobocinski FKA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846- 1854.
36. Rocha V, Locatelli F. Searching for alternative donors of haematopoietic stem cell for paediatric patients. Bone Marrow Transplant 2008; 41: 207- 214.
37. Issaragrisil S, Visuthisakchai S, Suvatte V, et al. Brief report: Transplantation of cord-blood stem cells into a patient with severe thalassemia. N Engl J Med 1995; 332: 367- 369.
38. Brichard B, Vermylen C, Ninane J, et al. Persistence of fetal hemoglobin production after successful transplantation of cord blood stem cells in a patient with sickle cell anemia. J Pediatr 1996; 128: 241- 243.
39. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137- 2143.
40. Reed W, Smith R, Dekovic F, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101: 351- 357.
41. Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: Review of four-center experience. Pediatr Transplant 2007; 11: 641- 644.
42. Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17: 1375- 1382.
43. Gluckman E, Rocha V, Ionescu I, et al. on behalf of Eurocord-Netcord and EBMT. Results of unrelated cord blood transplant in Fanconi anemia patients: Risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant 2007; 13: 1073- 1082.
44. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: The effect of extended haplotypes. Blood 2002; 99: 4350- 4356.
45. La Nasa G, Littera R, Locatelli F, et al. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant 2007; 13: 1358- 1368.
46. van Besien K, Bartholomew A, Stock W, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 2000; 26: 445- 449.
47. Schleuning M, Stoetzer O, Waterhouse C, et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol 2002; 30: 7- 10.
48. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519- 528.
49. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361: 2309- 2317.
50. Borgna-Pignatti C, Marradi P, Rugolotto S, et al. Successful pregnancy after bone marrow transplantation for thalassaemia. Bone Marrow Transplant 1996; 18: 235- 236.
51. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045- 3052.
52. Locatelli F, Giorgiani G, Pession A, et al. Late effects in children after bone marrow transplantation: A review. Haematologica 1993; 78: 319- 328.